271 related articles for article (PubMed ID: 21724704)
1. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
Baron M; Hudson M; Steele R; Lo E;
J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
[TBL] [Abstract][Full Text] [Related]
2. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
[TBL] [Abstract][Full Text] [Related]
3. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
Lee TH; Lee JS; Park S; Lee KA; Kim HS
Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
[TBL] [Abstract][Full Text] [Related]
4. A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Gorga M; Mihai C; Soare AM; Dobrotă R; Gherghe AM; Stoica V
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S61-7. PubMed ID: 26316302
[TBL] [Abstract][Full Text] [Related]
5. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.
Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228
[TBL] [Abstract][Full Text] [Related]
6. Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.
Zekovic A; Damjanov N
Rheumatol Int; 2017 May; 37(5):735-741. PubMed ID: 28271157
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Bae S; Allanore Y; Coustet B; Maranian P; Khanna D
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S15-21. PubMed ID: 21586213
[TBL] [Abstract][Full Text] [Related]
9. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.
Taş YM; Derviş Hakim G; Keskinoğlu P; Kenar G; Yarkan H; Zengin B; Can G; Önen F; Akkoç N; Birlik M; Akarsu M
Turk J Gastroenterol; 2019 Mar; 30(3):234-241. PubMed ID: 30541712
[TBL] [Abstract][Full Text] [Related]
10. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis.
Nietert PJ; Mitchell HC; Bolster MB; Curran MY; Tilley BC; Silver RM
J Rheumatol; 2005 Jan; 32(1):51-7. PubMed ID: 15630725
[TBL] [Abstract][Full Text] [Related]
11. Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis.
Omair MA; Lee P
J Rheumatol; 2012 May; 39(5):992-6. PubMed ID: 22467930
[TBL] [Abstract][Full Text] [Related]
12. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
[TBL] [Abstract][Full Text] [Related]
13. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey.
Rannou F; Poiraudeau S; Berezné A; Baubet T; Le-Guern V; Cabane J; Guillevin L; Revel M; Fermanian J; Mouthon L
Arthritis Rheum; 2007 Feb; 57(1):94-102. PubMed ID: 17266096
[TBL] [Abstract][Full Text] [Related]
14. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
[TBL] [Abstract][Full Text] [Related]
15. Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients.
Thombs BD; Hudson M; Bassel M; Taillefer SS; Baron M;
Arthritis Rheum; 2009 Jul; 61(7):966-73. PubMed ID: 19565539
[TBL] [Abstract][Full Text] [Related]
16. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS).
Pope J
Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S98-111. PubMed ID: 22588774
[No Abstract] [Full Text] [Related]
17. Validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort.
Low AHL; Xin X; Law WG; Teng GG; Santosa A; Lim A; Chan G; Ng SC; Thumboo J
Clin Rheumatol; 2017 Jul; 36(7):1643-1648. PubMed ID: 28058539
[TBL] [Abstract][Full Text] [Related]
18. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Khanna D; Furst DE; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Hays RD
J Rheumatol; 2011 Sep; 38(9):1920-4. PubMed ID: 21724699
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of Hebrew version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0.
Ozeri D; Peretz S; Oppenheim A; Watad A; Lidar M; Braun-Moscovici Y
J Scleroderma Relat Disord; 2023 Feb; 8(1):31-35. PubMed ID: 36743811
[TBL] [Abstract][Full Text] [Related]
20. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
